

TEMPLATE INSTRUCTIONS

The following template is organized by elements required to be submitted in the Real World Testing results report. Each section provides a field for submitting responses and/or explanations for how the health IT developer addressed each required element in their Real World Testing approach. These fields serve as a foundation of information required for developing a Real World Testing results report and can be expanded with additional rows or columns to address the specific needs of the Real World Testing results being submitted.

GENERAL INFORMATION

Plan Report ID Number: [For ONC-Authorized Certification Body use only]

Developer Name: US Monitoring, Inc.

Product Name(s): USMON Databse

Version Number(s): 13

Certified Health IT Product List (CHPL) ID(s): 15.99.3011.US01.13.01.221220

Developer Real World Testing Plan Page URL: https://usmon/10350_RWT_Plan_CY2025_11152024.pdf

Developer Real World Testing Results Report Page URL: <https://usmon.disclosure.html>

[OPTIONAL] CHANGES TO ORIGINAL PLAN

If a developer has made any changes to their approach for Real World Testing that differs from what was outlined in their plan, note these changes here.

Summary of Change [Summarize each element that changed between the plan and actual execution of Real World Testing]	Reason [Describe the reason this change occurred]	Impact [Describe what impact this change had on the execution of your Real World Testing activities]
N/A	N/A	N/A

[IF APPLICABLE] ICS PRODUCT(S)

If a developer chose to utilize inherited certified status (ICS) for a product originally outlined in their Real World Testing plan, the ICS products must be included in Real World Testing if the originating listing is withdrawn following ICS certification.

ICS Products	
Product Name(s):	N/A
Version Number(s):	
CHPL ID(s):	
Date(s) of ICS Certification:	

[IF APPLICABLE] WITHDRAWN PRODUCT(S)

If a developer withdrew any products within the past year that were previously included in their Real World Testing plan, please provide the following information.

Withdrawn Products	
Product Name(s):	N/A
Version Number(s):	
CHPL ID(s):	
Date(s) Withdrawn:	
Inclusion of Data in Results Report: [Provide a statement as to whether any data was captured on the withdrawn products. If so, this data should be identified in the results report.]	

SUMMARY OF TESTING METHODS AND KEY FINDINGS

Provide a summary of the Real World Testing methods deployed to demonstrate real-world interoperability, including any challenges or lessons learned from the chosen approach. Summarize how the results that will be shared in this report demonstrate real-world interoperability.

If any non-conformities were discovered and reported to the ONC-ACB during testing, outline these incidences and how they were addressed.

Note: A single Real World Testing results report may address multiple products and certification criteria for multiple care settings.

Real-world interoperability testing of the USMON Database application and potential usage by our clients concluded that all certified criteria in our Real World Test Plan for the plan year 2025 are determined to be functionally sound. Test methodologies include review of audit logs and reports to demonstrate the use by intended providers. As this review documented no usage, as was expected based on the normal workflow of the intended application, synthetic data was used to test and confirm consistent functionality. The Inferno Test Kit was utilized to ensure USMON Database system could securely connect and share patient data via FHIR APIs, checking for SMART app launches, user permissions, and the ability to revoke access show the usefulness of deployed features, as well as validated quality assurance of product features

STANDARDS VERSION ADVANCEMENT PROCESS (SVAP) STANDARDS UPDATES

Voluntary standards updates must be addressed in the Real World Testing results report. Real World Testing results reports must include all certified health IT updated to newer versions of standards prior to August 31 of the year in which the updates were made for the submitted plan.

Indicate as to whether voluntary SVAP standards are leveraged as part of the certification of your health IT product(s).

Yes, I have products certified with voluntary SVAP standards. (If yes, please complete the table below.

No, none of my products include these voluntary standards.

Standard (and version)	
Updated certification criteria and associated product	
Health IT Module CHPL ID	
Date of ONC-ACB notification	
Date of customer notification	
Conformance method and measurement/metric(s)	

Care Setting(s)

The expectation is that a developer’s Real World Testing is conducted within each type of clinical setting in which their certified health IT is marketed. Health IT developers are not required to test their certified health IT in every setting in which it is marketed for use.

List each care setting that was tested.

Care Setting: Inpatient and ambulatory

The use of USMON Database facilitates the care of patients undergoing procedures that require the monitoring of electrophysiological methods to monitor the nervous system during surgery

Metrics and Outcomes

Health IT developers should detail outcomes from their testing that successfully demonstrate that the certified health IT:

1. is compliant with the certification criteria, including the required technical standards and vocabulary codes sets;
2. is exchanging electronic health information (EHI) in the care and practice settings for which it is marketed for use; and/or,
3. EHI is received by and used in the certified health IT.

(from 85 FR 25766)

Health IT developers could also detail outcomes that did not result from their measurement approach if that better describes their efforts.

Within this section, health IT developers should also describe how the specific data collected from their Real World Testing measures demonstrate their results. Where possible, context should be provided to the measures and results to understand the number of sites/users/transactions tested for the specified measures (i.e., the denominator for comparison to the reported results). If applicable, any Relied Upon Software that is used to meet a criterion’s requirements should be included in this section.

Measurement/ Metric	Associated Criterion(a)	Relied Upon Software (if applicable)	Outcomes	Challenges Encountered (if applicable)
Standardized API	170.315 (g)(10)	None	Over a 90-day period: *FHIR validations executed: 20 *Successful responses: 20/20 *Third party registrations: 0 *External usage: 0/0 Details in Summary of Testing	None

KEY MILESTONES

Include a list of key milestones that were met during the Real World Testing process. Include details on how and when the developer implemented measures and collected data. Key milestones should be relevant and directly related to outcomes discussed.

For each key milestone, describe when Real World Testing began in specific care settings and the date/timeframe during which data was collected.

Key Milestone	Care Setting	Date/Timeframe
Analyze and plan method(s) to determine if the expected low or no use of (g)(10) can be determined. In the absence of no use, determine method test required functionality	Inpatient and ambulatory	Q1 2025
Identify the 90-day period for review of audit logs and data analysis. We will access audit logs and authorization requests to determine frequency of use. If none exist, we will test the authentication and FHIR servers with an appropriate testing tool.	Inpatient and ambulatory	Q2 and Q3
Generate Real World Test report and submit to ONC ATCB	Inpatient and ambulatory	Q4

ATTESTATION

The Real World Testing Results Template must include the following attestation signed by the Health IT Developer Authorized representative.

Note: The Results must be approved by a Health IT Developer authorized representative capable of binding the Health IT Developer for execution of the plan and include the representative's contact information.

This Real World Testing Results Report is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the Health IT Developer's Real World Testing requirements.

Authorized Representative Name: Michael Scholin

Authorized Representative Email: mike@usmon.com

Authorized Representative Phone: (608) 237-1731

Authorized Representative Signature: *Michael Scholin*

Date: 1/5/26